Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With GCSF (Filgrastim)

Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With Granulocyte Colony-stimulating Factor (Filgrastim)

This is a study of plasma HBP -levels of a previously published trial of G-CSF in critically ill patients (Pettila et al. Critical Care Medicine 2000). The original study was a prospective, randomised, double-blind, placebo-controlled trial of filgrastim in patients with acute respiratory failure requiring intubation. In this substudy, the investigators evaluated the effect of filgrastim on HBP -concentrations in critically ill patients.

Criteria for original study. For the substudy, all these patients were included.

Inclusion Criteria:

• Age > 18 years
• Admitted to the ICU no longer than 12 hrs before study entry
• Intubated because of ventilation insufficiency no longer than 48 hrs before study entry
• Clinically expected stay in the ICU > 48 hrs
• Informed consent

Exclusion Criteria:

• Pregnant or nursing
• Total leukocyte count of > 50,000/mm3
• Administration of filgrastim, sargramostim, or other biological response modifiers within 7 days before study entry
• Known hypersensitivity or allergic reaction to Escherichia coli-derived products
• Participation in another drug study